Analysis of the Coagulopathy Developed by COVID-19 Infected Patients

CompletedOBSERVATIONAL
Enrollment

175

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

February 14, 2022

Study Completion Date

June 2, 2022

Conditions
SepsisBlood Coagulation DisordersThrombinDisseminated Intravascular CoagulationCOVID-19
Interventions
OTHER

Thrombin generation test assay

lag time, initial velocity, time-to-peak, thrombin peak, total thrombin generation time, extrinsic thrombin potential (ETP). Crude quantitative values and relative values (%, by reference to the one obtained with an invariant reference plasma). Both without the addition of purified thrombomodulin (TM-) and with the addition of purified thrombomodulin (TM+). The ability of TM to inhibit thrombin generation will be calculated as follows: \[ETP (%)(TM+) / ETP (%)(TM-)\].

OTHER

Fibrin generation markers assays

D-dimers (coagulation plus fibrinolysis), soluble fibrin monomers (coagulation only)

Trial Locations (4)

Unknown

CHU de Bordeaux, Bordeaux

CHU de Limoges, Limoges

CHU de Montpellier, Montpellier

CHU de Nimes, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT04356950 - Analysis of the Coagulopathy Developed by COVID-19 Infected Patients | Biotech Hunter | Biotech Hunter